Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.
Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Bilen MA, et al. Among authors: campbell mt. Oncotarget. 2016 Dec 27;7(52):86280-86289. doi: 10.18632/oncotarget.13380. Oncotarget. 2016. PMID: 27861143 Free PMC article.
Recent developments in the management of germ cell tumors.
Msaouel P, Bilen MA, Zhang M, Campbell M, Wang J, Tu SM. Msaouel P, et al. Among authors: campbell m. Curr Opin Oncol. 2017 May;29(3):172-178. doi: 10.1097/CCO.0000000000000361. Curr Opin Oncol. 2017. PMID: 28151756 Free PMC article.
Optimizing management of upper tract urothelial carcinoma.
Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Campbell MT, et al. Urol Oncol. 2017 Jul;35(7):492-498. doi: 10.1016/j.urolonc.2017.05.009. Epub 2017 Jun 1. Urol Oncol. 2017. PMID: 28579283 Review.
Targeting advanced urothelial carcinoma-developing strategies.
Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Alhalabi O, et al. Among authors: campbell m. Curr Opin Oncol. 2019 May;31(3):207-215. doi: 10.1097/CCO.0000000000000532. Curr Opin Oncol. 2019. PMID: 30844889 Review.
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Shah AY, et al. Among authors: campbell mt. Eur J Cancer. 2019 Jun;114:67-75. doi: 10.1016/j.ejca.2019.04.003. Epub 2019 May 7. Eur J Cancer. 2019. PMID: 31075726 Free PMC article.
Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Chahoud J, et al. Among authors: campbell mt. Oncologist. 2020 Mar;25(3):252-258. doi: 10.1634/theoncologist.2019-0372. Epub 2019 Sep 9. Oncologist. 2020. PMID: 32162795 Free PMC article.
Phase 2 study of pembrolizumab in patients with advanced rare cancers.
Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Naing A, et al. Among authors: campbell m. J Immunother Cancer. 2020 Mar;8(1):e000347. doi: 10.1136/jitc-2019-000347. J Immunother Cancer. 2020. PMID: 32188704 Free PMC article. Clinical Trial.
5,412 results